G-CSF and EPO are never used clinically before a primary therapy because of their ability to promote tumor growth [personal communication from D. Douer], and TPO and SCF, which are no longer being pursued clinically, also proliferate tumor cells [65,66]. This evidence concerns the gene CSF3 and neoplasm.